Navigation Links
Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
Date:2/12/2009

- Management to discuss fourth quarter financial results -

LAVAL, QC, Feb. 12 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Thursday, February 26 at 8:30 a.m. (ET) to discuss its fourth quarter 2008 financial results. Labopharm will report its fourth quarter 2008 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3416 or 1-800-732-9307. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, March 5, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21295388 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labopharm.com.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... York, New York (PRWEB) , ... January 24, 2017 , ... ... for Brazilian butt lifts is on the rise. According to the American Society ... augmentations since 2000. On average, these procedures are performed every 30 minutes of every ...
(Date:1/24/2017)... PA (PRWEB) , ... January 24, 2017 , ... ... showcase its newest technology offering, Processing Assurance Control Equipment (PACE), at the International ... 2, 2017. , PeroxyChem’s booth will highlight the new technology that is used ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups have been ... 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and CEO Kevin ... will showcase their businesses on February 6, 2017, at Under Armour’s global headquarters ...
(Date:1/24/2017)... ... January 24, 2017 , ... Bellus Medical, a leader in medical aesthetics, today ... his new role Dr. Dobke will provide physician oversight for in-house clinical studies and ... of Plastic Surgery and Associate Professor of Surgery at UC San Diego Health and ...
(Date:1/24/2017)... ... January 24, 2017 , ... Inspiration, ... , Well-meaning studies such as the Fordham Institute’s High Stakes for High ... students, such as including gifted or high-achieving students as a subgroup and reporting ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... GERMANTOWN, Md. , and GAITHERSBURG, Md. ... XON ), a leader in the engineering and ... health of the planet, today announced that it has entered ... (NASDAQ: GNVC ), a clinical-stage company and pioneer ... Intrexon intends to integrate and expand upon GenVec,s expertise ...
(Date:1/24/2017)... 2017   QR Pharma , Inc., a ... therapies for the treatment of Alzheimer,s, Parkinson,s and ... four world-class key opinion leaders to its Scientific ... Pharma,s previous roster of impressive advisors in order ... the development of the breakthrough mechanism of action ...
(Date:1/24/2017)... Jan 24, 2017 Research and Markets has ... - Sensor, Actuator - Forecast to 2025" report to their ... Global ... 17.6% over the next decade to reach approximately $76.24 million by ... is witnessing include growing count of labs using optogentic techniques for ...
Breaking Medicine Technology: